Telehealth is now a permanent part of healthcare delivery—and so are the rules governing controlled-substance prescribing. The DEA has extended telehealth prescribing flexibilities for controlled substances through December 31, 2026, allowing medical practices to continue prescribing certain medications via telehealth under clearly defined requirements.
If your practice prescribes Schedule II–V controlled substances, these rules apply to you right now. Compliance expectations are no longer evolving—they are established. Practices are expected to be operating fully within the 2026 framework.
Find out what is allowed in 2026, how prior rule changes shaped today’s requirements, and what your practice should be doing now to stay compliant and protect patient access.
Why the DEA Telehealth Extension Matters in 2026
Telehealth is no longer viewed by regulators as a temporary or emergency service. It is a standard modality of care used across behavioral health, chronic care management, medication monitoring, and follow-up services.
The DEA’s extension through 2026 ensures patients continue to access necessary medications while reinforcing safeguards against diversion and misuse. In 2026, regulators expect practices to demonstrate that telehealth prescribing is intentional, documented, and monitored—not casual or automatic.
Practices that fail to align workflows with current expectations face increased audit and enforcement risk.
What Is Allowed in 2026 Under Current DEA Rules
As of January 2026, telehealth prescribing of controlled substances remains permitted under federal law, provided all requirements are met.
Your practice may prescribe Schedule II–V controlled substances via telehealth when clinically appropriate, allowed under state law, and supported by documentation. Initial prescriptions may be issued via telehealth, and refills may continue, as long as required follow-up conditions are satisfied.
Telehealth prescribing remains especially critical for mental health and substance-use-disorder treatment, where interruptions in care can result in significant patient harm.
How We Got Here: What Changed in 2024 and 2025
In 2024, the DEA continued temporary telehealth prescribing flexibilities that originated during the COVID-19 Public Health Emergency. During that year, you were allowed to prescribe controlled substances via telehealth without a prior in-person visit while preparing for longer-term rules.
In 2025, the DEA implemented an Interim Final Rule, formally shifting from temporary flexibility to a structured regulatory framework. That rule introduced the requirement for in-person follow-up visits within a defined timeframe for ongoing prescribing.
Those changes are no longer pending. They are the foundation of how telehealth prescribing operates today.
What Is Required Now in 2026
In 2026, practices are expected to be fully compliant with the DEA’s extended telehealth prescribing rules—not in transition.
This means telehealth prescribing continues, but it must be supported by a clearly established practitioner-patient relationship, appropriate follow-up care, and consistent monitoring. In-person visits must occur when required and must be documented in the medical record.
Practices that failed to adjust workflows in 2025 should correct gaps immediately to avoid compliance exposure.
Controlled vs. Non-Controlled Medications in Telehealth
Controlled substances continue to carry higher regulatory scrutiny than non-controlled medications.
While non-controlled prescriptions often involve fewer federal restrictions, controlled substances require enhanced documentation, justification, and oversight. Applying the wrong standard to the wrong medication category is a common audit trigger.
Clear internal protocols help staff avoid errors during scheduling, documentation, and prescribing.
State Law Still Applies in 2026
DEA rules establish a federal baseline—but state law still governs telehealth practice.
You must comply with state licensure rules, state telehealth laws, and state-specific prescribing limitations. Some states impose stricter requirements than federal law, including additional in-person visit mandates or documentation standards.
Practices serving patients across state lines should routinely review state requirements to avoid inadvertent violations.
What Your Practice Should Be Doing Right Now
- Confirm In-Person Follow-Up Compliance
Patients who initiated controlled medications via telehealth must now have documented, timely in-person visits when required. Scheduling systems should actively track and prompt these visits.
- Audit Telehealth Prescribing Records
Practices should regularly review charts to confirm telehealth encounters are clearly identified, medical necessity is documented, and follow-up plans are completed. Audits should focus on high-risk medications and long-term prescriptions.
- Update Policies and Procedures
Any policies referencing temporary extensions or outdated timelines should be revised. Written policies should clearly reflect 2026 requirements, staff responsibilities, and escalation processes.
- Train Staff Across All Roles
Compliance failures often occur outside the exam room. Front-desk staff, schedulers, billers, and clinical staff must all understand how telehealth prescribing works today.
Compliance Expectations Are Higher in 2026
Telehealth prescribing remains an active enforcement focus.
Regulators expect practices to demonstrate consistent clinical decision-making, ongoing patient monitoring, and safeguards against misuse. Documentation must clearly support why telehealth prescribing is appropriate for each patient.
Flexibility does not reduce accountability—and enforcement actions increasingly reflect that reality.
Final Takeaway for 2026
Telehealth prescribing of controlled substances is allowed through December 31, 2026, but only for practices operating under today’s rules.
What began as temporary flexibility is now a permanent operating framework. Practices that rely on outdated assumptions from 2024 or early 2025 are at risk.
Operating confidently in 2026 requires clear workflows, trained staff, and consistent documentation.
| Get the Full 2026 Telehealth Billing & Compliance Picture Prescribing rules are only one piece of telehealth compliance in 2026. Billing requirements, payer policies, and documentation standards continue to evolve. Get complete 2026 telehealth billing and compliance guidance by watching this on-demand training. This training helps ensure your practice is not only compliant—but paid correctly and protected while delivering telehealth services. |
References:
https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html